Literature DB >> 2835388

Kinetics of specific immunoglobulins M, E, A, and G in congenital, primary, and secondary cytomegalovirus infection studied by antibody-capture enzyme-linked immunosorbent assay.

S L Nielsen1, I Sørensen, H K Andersen.   

Abstract

Antibody-capture enzyme-linked immunosorbent assay (ELISA) using enzyme-labeled cytomegalovirus (CMV) nuclear antigen is a reliable and easily performed test suitable for routine use. As the serologic response to CMV infection may, however, vary considerably among patients, we have studied the kinetics of CMV-specific immunoglobulin M (IgM), IgE, IgA, and IgG antibodies in 352 sera from 61 patients by using antibody-capture ELISA and complement fixation (CF) tests. In a CMV mononucleosis group (n = 17), most patients had antibodies of all four immunoglobulin classes, but antibody levels decreased rapidly, with half the patients having a borderline-positive or a negative reaction for all classes, except IgG, 2 months after the appearance of symptoms. Twelve patients with a primary CMV infection after renal or bone marrow transplantation also developed all immunoglobulin-class antibodies. In only two patients did CMV IgM and IgE antibodies precede seroconversion of CF antibodies, and in one patient, these antibodies lagged months behind. Most patients had all classes of CMV antibodies, except IgA, for a year or more. Among 10 transplant patients with a secondary CMV infection, 50% had long-lasting IgM antibodies, and very few had IgE or IgA antibodies, but all had IgG antibodies to CMV. In 13 infected infants, the CMV-specific serologic response was also characterized by long-lasting IgM, IgE, and IgG antibodies. Two patients did not develop detectable IgM antibodies, and one of these did not show IgE antibodies either. The IgA response in infants as a whole was lacking; a few, however, were borderline positive. Of the nine acquired immunodeficiency syndrome patients with CMV infection studied during their last year of life, only one had antibodies in all four classes, the rest had only CF antibodies, and all except for one had IgG-class antibodies. All sera studied were also tested against a control antigen produced from noninfected cell nuclei. It was found that some patients developed antibodies to nuclear antigens in parallel with the rise in specific antibodies. The nonspecific antibodies occurred in all four classes, but most often they were of the IgM class. Addition of unlabeled control antigen to the conjugates was not always sufficient to abort this nonspecific reaction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2835388      PMCID: PMC266401          DOI: 10.1128/jcm.26.4.654-661.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  Smooth-muscle antibodies and other tissue antibodies in cytomegalovirus infection.

Authors:  P Andersen; H K Andersen
Journal:  Clin Exp Immunol       Date:  1975-10       Impact factor: 4.330

2.  Antibody response to cytomegalovirus after renal transplantation: comparison of patients with primary and recurrent infections.

Authors:  R F Pass; P D Griffiths; A M August
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

3.  Detection of virus-specific IgA antibodies in serum of kidney transplant patients with recurrent cytomegalovirus infection by enzymeimmuno and radioimmunoassay techniques.

Authors:  I Sarov; E Levy; M Aymard; Y Chardonnet; S Bosshard; J P Revillard; M Friedman; E Nord; M Greiff; H Haikin
Journal:  Clin Exp Immunol       Date:  1982-05       Impact factor: 4.330

4.  The detection of antibodies to cytomegalovirus in the sera of renal transplant patients by an IgM antibody capture assay.

Authors:  S Sutherland; J D Briggs
Journal:  J Med Virol       Date:  1983       Impact factor: 2.327

5.  Improvement of serological diagnosis of neonatal cytomegalovirus infection by simultaneously testing for specific immunoglobulins E and M by antibody-capture enzyme-linked immunosorbent assay.

Authors:  S L Nielsen; E Rønholm; I Sørensen; P Jaeger; H K Andersen
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

6.  A prospective study on the incidence and significance of congenital cytomegalovirus infection.

Authors:  H K Andersen; K Brostrøm; K B Hansen; J Leerhøy; M Pedersen; O Osterballe; U Felsager; S Mogensen
Journal:  Acta Paediatr Scand       Date:  1979-05

7.  Cytomegalovirus infection after bone marrow transplantation: relation of pneumonia to postgrafting immunosuppressive treatment.

Authors:  P Skinhøj; H K Andersen; J Møller; N Jacobsen
Journal:  J Med Virol       Date:  1984       Impact factor: 2.327

8.  Virus-specific IgG and IgM antibodies in normal and immunocompromised subjects infected with cytomegalovirus.

Authors:  L Rasmussen; D Kelsall; R Nelson; W Carney; M Hirsch; D Winston; J Preiksaitis; T C Merigan
Journal:  J Infect Dis       Date:  1982-02       Impact factor: 5.226

9.  Solid-phase radioimmunoassay of serum IgG, IgM, and IgA antibodies to cytomegalovirus.

Authors:  E G Torfason; C Källander; P Halonen
Journal:  J Med Virol       Date:  1981       Impact factor: 2.327

10.  Determination of IgA antibodies to human cytomegalovirus by enzyme-linked immunosorbent assay (ELISA).

Authors:  E Levy; I Sarov
Journal:  J Med Virol       Date:  1980       Impact factor: 2.327

View more
  26 in total

1.  Long-term persistence of immunoglobulin A (IgA) and IgM antibodies against human cytomegalovirus in solid-organ transplant recipients.

Authors:  B R Eing; H G Baumeister; J E Kuehn; G May
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

2.  Avidity of immunoglobulin G directed against human cytomegalovirus during primary and secondary infections in immunocompetent and immunocompromised subjects.

Authors:  T Lazzarotto; P Spezzacatena; P Pradelli; D A Abate; S Varani; M P Landini
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

3.  Comparison of the Vitek Immunodiagnostic Assay System with three immunoassay systems for detection of cytomegalovirus-specific immunoglobulin G.

Authors:  D K Hopson; A C Niles; P R Murray
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

4.  Measurement of the sensitivity of different commercial assays in the diagnosis of CMV infection in pregnancy.

Authors:  M Gentile; C Galli; P Pagnotti; P Di Marco; S Tzantzoglou; F Bellomi; M L Ferreri; C Selvaggi; G Antonelli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-10       Impact factor: 3.267

5.  Immunoglobulin A-specific serodiagnosis of acute human cytomegalovirus infection by using recombinant viral antigens.

Authors:  R Vornhagen; W Hinderer; H H Sonneborn; G Bein; L Matter; T H The; G Jahn; B Plachter
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

6.  Quantitative measurement of cytomegalovirus-specific IgG and IgM antibodies in relation to cytomegalovirus antigenaemia and disease activity in kidney recipients with an active cytomegalovirus infection.

Authors:  M Van der Giessen; A P van den Berg; W van der Bij; S Postma; W J van Son; T H The
Journal:  Clin Exp Immunol       Date:  1990-04       Impact factor: 4.330

7.  A novel Western blot test containing both viral and recombinant proteins for anticytomegalovirus immunoglobulin M detection.

Authors:  T Lazzarotto; G T Maine; P Dal Monte; A Ripalti; M P Landini
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

8.  Specific serum immunoglobulin D, detected by antibody capture enzyme-linked immunosorbent assay (ELISA), in cytomegalovirus infection.

Authors:  J Mortensen; S L Nielsen; I Sørensen; H K Andersen
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

9.  Diagnosis of human immunodeficiency virus infection using an immunoglobulin E-based assay.

Authors:  M Fletcher; M J Miguez-Burbano; G Shor-Posner; V Lopez; H Lai; M K Baum
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

10.  Improvement of serological diagnosis of human cytomegalovirus infection in renal transplant recipients by testing for specific immunoglobulin E by ELISA.

Authors:  B Weber; A Stemmler; W Ernst; E H Scheuerman; W Braun; H W Doerr
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.